Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Devyser Diagnostics AB, a prominent biotechnology company, specializes in the development, manufacturing, and distribution of diagnostic test kits built on unique genetic testing technology. The primary function of Devyser Diagnostics AB's products is to provide rapid and reliable diagnostic solutions in areas such as hereditary diseases, oncology, and post-transplantation monitoring. By enabling comprehensive genetic analysis, these kits help healthcare professionals deliver precise disease diagnostics and personalized treatment plans. Devyser’s technology plays a critical role in clinical laboratories worldwide, enhancing the accuracy and efficiency of DNA analysis. The company’s focus on innovation and quality has established it as a key player within the molecular diagnostics industry, gaining a reputation for simplifying complex genetic tests into user-friendly formats. These advancements not only improve patient outcomes but also streamline operations within the healthcare sector, particularly in genomics and precision medicine. Through continuous research and development, Devyser Diagnostics AB remains at the forefront of molecular diagnostics, driving advancements in genetic testing that are essential for modern healthcare frameworks.
kr 7.59
kr 0.28 (-3.56%)
EOD Jun 23, 2026 · Twelve Data
Operating margin is thin at 4.59%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 15.5% YoY with margins expanding 33.5pp.
Negative free cash flow of -kr 62M. The business is consuming cash, not generating it.
8.4x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 258M
▲ +15.5% YoY
Net Income (TTM)
kr 15M
▲ +86.3% YoY
Op. Margin
11.18%
▲ +33.5pp YoY
ROIC
2.23%
▲ +13.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 37M
▲ +51.4% YoY
Op. Cash Flow (TTM)
kr 14M
▲ +89.0% YoY
Net Debt
-kr 26M
Net Cash Position
Cash & Equiv.
kr 78M
3Y CAGR: +25.5%
Continue Research
At a P/E of 8.4, Devyser Diagnostics AB (DVYSR.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Devyser Diagnostics AB scores 53/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Devyser Diagnostics AB scores 53 out of 100 on Intrinsiqq's quality score, passing 4 of 7 checks, which makes it a mixed business on these measures. Recent fundamentals include a 11.2% operating margin and a 2.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DVYSR.XSTO's valuation and scores 53/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.